癌症研究
生物
癌症
EZH2型
PRC2
癌变
细胞生长
基因沉默
癌细胞
长非编码RNA
表观遗传学
下调和上调
遗传学
基因
作者
Ming Sun,Fengqi Nie,Yunfei Wang,Zhihong Zhang,Jiakai Hou,Dandan He,Min Xie,Lin Xu,Wei De,Zhaoxia Wang,Jun Wang
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2016-09-21
卷期号:76 (21): 6299-6310
被引量:437
标识
DOI:10.1158/0008-5472.can-16-0356
摘要
Abstract Long noncoding RNAs (lncRNA) have been implicated in human cancer but their mechanisms of action are mainly undocumented. In this study, we investigated lncRNA alterations that contribute to gastric cancer through an analysis of The Cancer Genome Atlas RNA sequencing data and other publicly available microarray data. Here we report the gastric cancer–associated lncRNA HOXA11-AS as a key regulator of gastric cancer development and progression. Patients with high HOXA11-AS expression had a shorter survival and poorer prognosis. In vitro and in vivo assays of HOXA11-AS alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, and apoptosis. Strikingly, high-throughput sequencing analysis after HOXA11-AS silencing highlighted alterations in cell proliferation and cell–cell adhesion pathways. Mechanistically, EZH2 along with the histone demethylase LSD1 or DNMT1 were recruited by HOXA11-AS, which functioned as a scaffold. HOXA11-AS also functioned as a molecular sponge for miR-1297, antagonizing its ability to repress EZH2 protein translation. In addition, we found that E2F1 was involved in HOXA11-AS activation in gastric cancer cells. Taken together, our findings support a model in which the EZH2/HOXA11-AS/LSD1 complex and HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastric cancer. Cancer Res; 76(21); 6299–310. ©2016 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI